Peripheral T-Cell Lymphoma Treatment Market 2027 By Therapy, End User | The Insight Partners

Peripheral T-Cell Lymphoma Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Therapy (Chemotherapy, Radiation Therapy, Monoclonal Antibodies Therapy, Others); End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others)

Report Code: TIPRE00015286 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Peripheral T-cell lymphomas (PTCLs) are an unusual and different group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called "T cells" and "natural killer (NK) cells". It is PTCL's origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In PTCL, the term "peripheral" seems not to refer to the extremities. It recognizes PTCL as cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin.

MARKET DYNAMICS

The peripheral T-cell lymphoma treatment market is driving due to an increasing prevalence of peripheral T-cell lymphoma and the new treatment launch. However, the disease's complexity is restricting the number of options for peripheral T-cell lymphoma treatment is expected to hamper the global peripheral T-cell lymphoma treatment market. Moreover, genetic research has led to enhancing knowledge of disease provides opportunities in the market.

MARKET SCOPE

The "Peripheral T-Cell Lymphoma Treatment Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of peripheral T-cell lymphoma treatment market with detailed market segmentation by therapy and end user. The peripheral T-cell lymphoma treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in peripheral T-cell lymphoma treatment market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The peripheral T-cell lymphoma treatment market is segmented on the basis of therapy and end user. Based on therapy, the market is segmented as chemotherapy, radiation therapy, monoclonal antibodies therapy, and others. Based on end user, the market is segmented as hospitals, clinics, ambulatory surgical centers, and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the peripheral T-cell lymphoma treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The peripheral T-cell lymphoma treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting peripheral T-cell lymphoma treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the peripheral T-cell lymphoma treatment market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the peripheral T-cell lymphoma treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from peripheral T-cell lymphoma treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for peripheral T-cell lymphoma treatment in the global market. Below mentioned is the list of few companies engaged in the peripheral T-cell lymphoma treatment market.

The report also includes the profiles of key players in peripheral T-cell lymphoma treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Merck
  •   Leadiant Biosciences
  •   Pfizer
  •   Pacira Pharmaceuticals (Skyepharma)
  •   Genmab AS
  •   Bristol-Myers Squibb
  •   Spectrum Pharmaceuticals
  •   Sigma-Tau Pharmaceuticals Inc.
  •   Celgene Corporation
  •   Solasia Pharma KK

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Peripheral T-Cell Lymphoma Treatment Market - By Therapy
1.3.2 Peripheral T-Cell Lymphoma Treatment Market - By End User
1.3.3 Peripheral T-Cell Lymphoma Treatment Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PERIPHERAL T-CELL LYMPHOMA TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PERIPHERAL T-CELL LYMPHOMA TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PERIPHERAL T-CELL LYMPHOMA TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. PERIPHERAL T-CELL LYMPHOMA TREATMENT - GLOBAL MARKET OVERVIEW
6.2. PERIPHERAL T-CELL LYMPHOMA TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. PERIPHERAL T-CELL LYMPHOMA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - THERAPY
7.1. OVERVIEW
7.2. THERAPY MARKET FORECASTS AND ANALYSIS
7.3. CHEMOTHERAPY
7.3.1. Overview
7.3.2. Chemotherapy Market Forecast and Analysis
7.4. RADIATION THERAPY
7.4.1. Overview
7.4.2. Radiation Therapy Market Forecast and Analysis
7.5. MONOCLONAL ANTIBODIES THERAPY
7.5.1. Overview
7.5.2. Monoclonal Antibodies Therapy Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. PERIPHERAL T-CELL LYMPHOMA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - END USER
8.1. OVERVIEW
8.2. END USER MARKET FORECASTS AND ANALYSIS
8.3. HOSPITALS
8.3.1. Overview
8.3.2. Hospitals Market Forecast and Analysis
8.4. CLINICS
8.4.1. Overview
8.4.2. Clinics Market Forecast and Analysis
8.5. AMBULATORY SURGICAL CENTERS
8.5.1. Overview
8.5.2. Ambulatory Surgical Centers Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. PERIPHERAL T-CELL LYMPHOMA TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Peripheral T-Cell Lymphoma Treatment Market Overview
9.1.2 North America Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis
9.1.3 North America Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By Therapy
9.1.4 North America Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By End User
9.1.5 North America Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By Countries
9.1.5.1 United States Peripheral T-Cell Lymphoma Treatment Market
9.1.5.1.1 United States Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.1.5.1.2 United States Peripheral T-Cell Lymphoma Treatment Market by End User
9.1.5.2 Canada Peripheral T-Cell Lymphoma Treatment Market
9.1.5.2.1 Canada Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.1.5.2.2 Canada Peripheral T-Cell Lymphoma Treatment Market by End User
9.1.5.3 Mexico Peripheral T-Cell Lymphoma Treatment Market
9.1.5.3.1 Mexico Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.1.5.3.2 Mexico Peripheral T-Cell Lymphoma Treatment Market by End User
9.2. EUROPE
9.2.1 Europe Peripheral T-Cell Lymphoma Treatment Market Overview
9.2.2 Europe Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis
9.2.3 Europe Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By Therapy
9.2.4 Europe Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By End User
9.2.5 Europe Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Peripheral T-Cell Lymphoma Treatment Market
9.2.5.1.1 Germany Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.2.5.1.2 Germany Peripheral T-Cell Lymphoma Treatment Market by End User
9.2.5.2 France Peripheral T-Cell Lymphoma Treatment Market
9.2.5.2.1 France Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.2.5.2.2 France Peripheral T-Cell Lymphoma Treatment Market by End User
9.2.5.3 Italy Peripheral T-Cell Lymphoma Treatment Market
9.2.5.3.1 Italy Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.2.5.3.2 Italy Peripheral T-Cell Lymphoma Treatment Market by End User
9.2.5.4 Spain Peripheral T-Cell Lymphoma Treatment Market
9.2.5.4.1 Spain Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.2.5.4.2 Spain Peripheral T-Cell Lymphoma Treatment Market by End User
9.2.5.5 United Kingdom Peripheral T-Cell Lymphoma Treatment Market
9.2.5.5.1 United Kingdom Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.2.5.5.2 United Kingdom Peripheral T-Cell Lymphoma Treatment Market by End User
9.2.5.6 Rest of Europe Peripheral T-Cell Lymphoma Treatment Market
9.2.5.6.1 Rest of Europe Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.2.5.6.2 Rest of Europe Peripheral T-Cell Lymphoma Treatment Market by End User
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Peripheral T-Cell Lymphoma Treatment Market Overview
9.3.2 Asia-Pacific Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis
9.3.3 Asia-Pacific Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By Therapy
9.3.4 Asia-Pacific Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By End User
9.3.5 Asia-Pacific Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Peripheral T-Cell Lymphoma Treatment Market
9.3.5.1.1 Australia Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.3.5.1.2 Australia Peripheral T-Cell Lymphoma Treatment Market by End User
9.3.5.2 China Peripheral T-Cell Lymphoma Treatment Market
9.3.5.2.1 China Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.3.5.2.2 China Peripheral T-Cell Lymphoma Treatment Market by End User
9.3.5.3 India Peripheral T-Cell Lymphoma Treatment Market
9.3.5.3.1 India Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.3.5.3.2 India Peripheral T-Cell Lymphoma Treatment Market by End User
9.3.5.4 Japan Peripheral T-Cell Lymphoma Treatment Market
9.3.5.4.1 Japan Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.3.5.4.2 Japan Peripheral T-Cell Lymphoma Treatment Market by End User
9.3.5.5 South Korea Peripheral T-Cell Lymphoma Treatment Market
9.3.5.5.1 South Korea Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.3.5.5.2 South Korea Peripheral T-Cell Lymphoma Treatment Market by End User
9.3.5.6 Rest of Asia-Pacific Peripheral T-Cell Lymphoma Treatment Market
9.3.5.6.1 Rest of Asia-Pacific Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.3.5.6.2 Rest of Asia-Pacific Peripheral T-Cell Lymphoma Treatment Market by End User
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Peripheral T-Cell Lymphoma Treatment Market Overview
9.4.2 Middle East and Africa Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis
9.4.3 Middle East and Africa Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By Therapy
9.4.4 Middle East and Africa Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By End User
9.4.5 Middle East and Africa Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Peripheral T-Cell Lymphoma Treatment Market
9.4.5.1.1 South Africa Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.4.5.1.2 South Africa Peripheral T-Cell Lymphoma Treatment Market by End User
9.4.5.2 Saudi Arabia Peripheral T-Cell Lymphoma Treatment Market
9.4.5.2.1 Saudi Arabia Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.4.5.2.2 Saudi Arabia Peripheral T-Cell Lymphoma Treatment Market by End User
9.4.5.3 U.A.E Peripheral T-Cell Lymphoma Treatment Market
9.4.5.3.1 U.A.E Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.4.5.3.2 U.A.E Peripheral T-Cell Lymphoma Treatment Market by End User
9.4.5.4 Rest of Middle East and Africa Peripheral T-Cell Lymphoma Treatment Market
9.4.5.4.1 Rest of Middle East and Africa Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.4.5.4.2 Rest of Middle East and Africa Peripheral T-Cell Lymphoma Treatment Market by End User
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Peripheral T-Cell Lymphoma Treatment Market Overview
9.5.2 South and Central America Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis
9.5.3 South and Central America Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By Therapy
9.5.4 South and Central America Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By End User
9.5.5 South and Central America Peripheral T-Cell Lymphoma Treatment Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Peripheral T-Cell Lymphoma Treatment Market
9.5.5.1.1 Brazil Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.5.5.1.2 Brazil Peripheral T-Cell Lymphoma Treatment Market by End User
9.5.5.2 Argentina Peripheral T-Cell Lymphoma Treatment Market
9.5.5.2.1 Argentina Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.5.5.2.2 Argentina Peripheral T-Cell Lymphoma Treatment Market by End User
9.5.5.3 Rest of South and Central America Peripheral T-Cell Lymphoma Treatment Market
9.5.5.3.1 Rest of South and Central America Peripheral T-Cell Lymphoma Treatment Market by Therapy
9.5.5.3.2 Rest of South and Central America Peripheral T-Cell Lymphoma Treatment Market by End User
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PERIPHERAL T-CELL LYMPHOMA TREATMENT MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. PERIPHERAL T-CELL LYMPHOMA TREATMENT MARKET, KEY COMPANY PROFILES
12.1. MERCK
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. LEADIANT BIOSCIENCES
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. PFIZER
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. PACIRA PHARMACEUTICALS (SKYEPHARMA)
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. GENMAB AS
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. BRISTOL-MYERS SQUIBB
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. SPECTRUM PHARMACEUTICALS
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. SIGMA-TAU PHARMACEUTICALS INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. CELGENE CORPORATION
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SOLASIA PHARMA KK
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Merck
2. Leadiant Biosciences
3. Pfizer
4. Pacira Pharmaceuticals (Skyepharma)
5. Genmab AS
6. Bristol-Myers Squibb
7. Spectrum Pharmaceuticals
8. Sigma-Tau Pharmaceuticals Inc.
9. Celgene Corporation
10. Solasia Pharma KK
TIPRE00015286
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking